Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss
- 19 February 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (5) , 3195-3211
Abstract
The melanocortin-4 receptor (MC4R) is a centrally expressed, class A GPCR that plays a key role in the regulation of appetite and food intake. Deficiencies in MC4R signaling result in hyperphagia and increased body mass in humans. Antagonism of MC4R signaling has the potential to mitigate decreased appetite and body weight loss in the setting of anorexia or cachexia due to underlying disease. Herein, we report on the identification of a series of orally bioavailable, small-molecule MC4R antagonists using a focused hit identification effort and the optimization of these antagonists to provide clinical candidate 23. Introduction of a spirocyclic conformational constraint allowed for simultaneous optimization of MC4R potency and ADME attributes while avoiding the production of hERG active metabolites observed in early series leads. Compound 23 is a potent and selective MC4R antagonist with robust efficacy in an aged rat model of cachexia and has progressed into clinical trials.Keywords
This publication has 54 references indexed in Scilit:
- Identification and in Vivo and in Vitro Characterization of Long Acting and Melanocortin 4 Receptor (MC4-R) Selective α-Melanocyte-Stimulating Hormone (α-MSH) AnaloguesJournal of Medicinal Chemistry, 2012
- The Melanocortin-4 Receptor: Physiology, Pharmacology, and PathophysiologyEndocrine Reviews, 2010
- Discovery of a Selective Small-Molecule Melanocortin-4 Receptor Agonist with Efficacy in a Pilot Study of Sexual Dysfunction in HumansJournal of Medicinal Chemistry, 2010
- Orally Available Selective Melanocortin-4 Receptor Antagonists Stimulate Food Intake and Reduce Cancer-Induced Cachexia in MicePLOS ONE, 2009
- Recent advances in the development of melanocortin-4 receptor ligandsExpert Opinion on Therapeutic Patents, 2008
- Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity RelationshipsJournal of Medicinal Chemistry, 2008
- Enantiopure 1,4-Benzoxazines via 1,2-Cyclic Sulfamidates. Synthesis of LevofloxacinOrganic Letters, 2007
- Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesityMolecular and Cellular Endocrinology, 2005
- Blunted hypothalamic neuropeptide gene expression in response to fasting, but preservation of feeding responses to AgRP in aging male Brown Norway ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Predicting therapeutic value in the lead optimization phase of drug discoveryNature Reviews Drug Discovery, 2003